3: Preventing complications of diabetes

Medical Journal of Australia

Volumn 179, Issue 9, 2003, Pages 498-503

  Bate, Katherine L ^a   Jerums, George ^a,b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GABAPENTIN; GEMFIBROZIL; GLUCOSE; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRBESARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SIMVASTATIN; SULFONYLUREA;

ABDOMINAL DISTENSION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DYSLIPIDEMIA; FREQUENCY ANALYSIS; HEALTH CARE COST; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; LOW DRUG DOSE; MICROALBUMINURIA; MICROANGIOPATHY; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; TREATMENT INDICATION; VASCULAR DISEASE;

EID: 0242522175     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2003.tb05655.x     Document Type: Review

References (31)

1. Dunstan D, Zimmet P, Welborn T, et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829-834.
2. Colagiuri S, Colagiuri R, Conway B. DiabCost Australia. Assessing the burden of Type 2 diabetes in Australia 2002. Available at: www.diabetes.net.au/PDF/DiabCostReport.pdf (accessed Oct 2003).
3. Gaede P, Vedal P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
4. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care 1979; 2: 120-126.
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
6. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.
7. Hansson L, Zanchetti A, Westerling S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
8. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259.
9. Sacks FM, Pfeffer MA, Braunwald E, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
11. Sever PS, Dahlof B, Ostergren J, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
13. Hu F, Stampfer M, Solomon C. Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med 2001; 134: 96-105.
14. Tuomilehto J, Lindstrom J, Uusitupa M, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
15. Shaw JE, Chisholm DJ. 1: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. Med J Aust 2003; 179: 379-383.
16. Stefanick ML, Mackey S, Wood PD, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998; 339: 12-20.
17. Trichopoulou A, Costacou T, Trichopoulos D, et al. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003; 348: 2599-2608.
18. Gilbertson HR, Brand-Miller JC, Werther GA, et al. The effect of flexible low glycemic index dietary advice versus measured carbohydrate exchange diets on glycemic control in children with type 1 diabetes. Diabetes Care 2001; 24: 1137-1143.
19. National Institutes of Health. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Available at: www.nhlbi.nih.gov/guidelines/hypertension (accessed Oct 2003).
20. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
21. Standards of medical care for patients with diabetes mellitus - American Diabetes Association. Diabetes Care 2003; 26 Suppl 1: S33-S50.
22. Marshall SM. Clinical features and management of diabetic nephropathy. In: Pickup JC, Williams G, editors. Textbook of Diabetes. Boston: Blackwell Publishing, 2003.
23. VanNewkirk MR, Weih L, Taylor HR, et al. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: The Visual Impairment Project. Ophthalmology 2001; 108: 960-967.
24. Fong DS, Aiello L, Gardner TW, et al. Diabetic retinopathy. Diabetes Care 2003; 26 Suppl 1: S99-S102.
25. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
26. Lewis EJ, Hunsicker LG, Rohde RD, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
27. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995; 99: 497-504.
28. Parving HH, Lehnert H, Brochner-Mortensen J, et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
29. Brenner BM, Cooper ME, De Zeeuw D, et al., for the RENAAL Study Investigators (Brigham and Women's Hospital, Boston; University of Melbourne, Victoria, Australia; Hennepin County Medical Center, Minneapolis). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
30. Lewis EJ, Hunsicker LG, Raz I, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
31. Rossing K, Christensen PK, Parving HH, et al. Dual blockade of the renin-angiotensin system in diabetic nephropathy: A randomized double-blind crossover study. Diabetes Care 2002; 25: 95-100.